Trial Profile
Efficacy and Safety Study of a Sequential Therapy of Tocilizumab (TCZ) and, if Initially Inadequately Responded to Tocilizumab (TCZ), Followed by Rituximab (RTX) in DMARD-IR Patients With Rheumatoid Arthritis (MIRAI)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Rituximab
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms MIRAI
- Sponsors Roche
- 16 Apr 2019 Primary endpoint (Early efficacy rate defined as Disease Activity Score (DAS28) remission 2.6 after 4 courses of tocilizumab (TCZ) treatment) has not been met, according to the results published in the Clinical and Experimental Rheumatology
- 16 Apr 2019 Results assessing the early and late responses in biological-naive patients with rheumatoid arthritis initiating tocilizumab and early tocilizumab non-responders who switched to rituximab, published in the Clinical and Experimental Rheumatology
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.